Oxyphencyclimine

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 318407

CAS#: 125-53-1 (free base)

Description: Oxyphencyclimine is a muscarinic receptor antagonist (MRA) anticholinergic drug (trade name Daricon) used in treating peptic ulcers.


Chemical Structure

img
Oxyphencyclimine
CAS# 125-53-1 (free base)

Theoretical Analysis

MedKoo Cat#: 318407
Name: Oxyphencyclimine
CAS#: 125-53-1 (free base)
Chemical Formula: C20H28N2O3
Exact Mass: 344.20999
Molecular Weight: 344.46
Elemental Analysis: C, 69.74; H, 8.19; N, 8.13; O, 13.93

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Related CAS #: 125-52-0 (HCl)   125-53-1 (free base)  

Synonym: Oxiphencycliminum; Manir; Antulcus; Caridan; Naridan; Zamanil; Oxifencicliminum; Oxyphencycliminum; Oxyphencycliminum [INN-Latin]; Daricol; Daricon

IUPAC/Chemical Name: (1-methyl-5,6-dihydro-4H-pyrimidin-2-yl)methyl 2-cyclohexyl-2-hydroxy-2-phenylacetate

InChi Key: DUDKAZCAISNGQN-UHFFFAOYSA-N

InChi Code: InChI=1S/C20H28N2O3/c1-22-14-8-13-21-18(22)15-25-19(23)20(24,16-9-4-2-5-10-16)17-11-6-3-7-12-17/h2,4-5,9-10,17,24H,3,6-8,11-15H2,1H3

SMILES Code: CN1CCCN=C1COC(=O)C(C2CCCCC2)(C3=CC=CC=C3)O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 344.46 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Klaphajone J, Kitisomprayoonkul W, Sriplakit S. Botulinum toxin type A injections for treating neurogenic detrusor overactivity combined with low-compliance bladder in patients with spinal cord lesions. Arch Phys Med Rehabil. 2005 Nov;86(11):2114-8. PubMed PMID: 16271557.

2: Cai H, Vigh G. Capillary electrophoretic separation of weak base enantiomers using the single-isomer heptakis-(2,3-dimethyl-6-sulfato)-beta-cyclodextrin as resolving agent and methanol as background electrolyte solvent. J Pharm Biomed Anal. 1998 Dec;18(4-5):615-21. PubMed PMID: 9919962.

3: Waelbroeck M, Camus J, Tastenoy M, Mutschler E, Strohmann C, Tacke R, Schjelderup L, Aasen A, Lambrecht G, Christophe J. Stereoselective interaction of procyclidine, hexahydro-difenidol, hexbutinol and oxyphencyclimine, and of related antagonists, with four muscarinic receptors. Eur J Pharmacol. 1992 Sep 1;227(1):33-42. PubMed PMID: 1426023.

4: Jensen JL, Brodin P, Berg T, Aars H. Parotid secretion of fluid, amylase and kallikrein during reflex stimulation under normal conditions and after acute administration of autonomic blocking agents in man. Acta Physiol Scand. 1991 Nov;143(3):321-9. PubMed PMID: 1722939.

5: Schjelderup L, Kozlowski MR, Weissman A, Aasen AJ. Antimuscarinic effects of (R)- and (S)- oxyphencyclimine hydrochloride. Pharm Res. 1988 Apr;5(4):236-7. PubMed PMID: 3247303.

6: Ebeid MY, Moussa BA, Abdel Malak AA. Analysis of some antispasmodic drugs: oxyphencyclimine and glycopyrronium bromide. Pharm Weekbl Sci. 1986 Oct 17;8(5):252-8. PubMed PMID: 3786107.

7: Morón F, Pena C, Cuesta E, Mózsik G, Jávor T. Comparative study of the cytoprotective effects of anticholinergic agents on the gastric mucosal lesions produced by intragastric administration of 0.6 M HCl in rats. Acta Physiol Hung. 1984;64(3-4):247-52. PubMed PMID: 6532117.

8: Goldenberg MM, Moore RB. Effect of nolinium bromide, cimetidine, and oxyphencyclimine on gastric hypersecretion induced by some secretagogues in the rat. Arch Int Pharmacodyn Ther. 1980 Sep;247(1):163-76. PubMed PMID: 7004367.

9: Heathcote BV, Parry M. Pirenzepine selectively inhibits gastric acid secretion: a comparative pharmacological study between pirenzepine and seven other antiacetylcholine drugs. Scand J Gastroenterol Suppl. 1980;66:15-26. PubMed PMID: 6113681.

10: Andersson S, Axelsson U, Sandström I. [Ocular side-effects in peroral treatment with anticholinergic agents]. Lakartidningen. 1979 Oct 17;76(42):3645-7. Swedish. PubMed PMID: 393924.